Track Cytosorbents Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cytosorbents Corporation CTSO · Stock Open Cytosorbents Corporation in new tab

4.80 USD
EPS
-5.80
P/B
-20.08
ROE
-336.21
Beta
1.48
Target Price
47.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-5.80
Book Value-0.24
Price to Book-20.08
% Insiders16.253%
Growth
Revenue Growth0.00%
Estimates
Target Mean Price47.50

DCF valuation

Model fair value for Cytosorbents Corporation (CTSO)
Result
Sign in to run the valuation for CTSO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 47.50 USD (low 15.00, high 80.00)
Low 15.00
Mean 47.50
High 80.00
Price 4.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Cytosorbents Corporation Logo Cytosorbents Corporation Analysis (CTSO)

United States Health Care Official Website Stock

Is Cytosorbents Corporation a good investment? Cytosorbents Corporation (CTSO) is currently trading at 4.80 USD. Market analysts have a consensus price target of 47.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cytosorbents Corporation is expected to release its next earnings report on March 24, 2027.

Investor FAQ

Does Cytosorbents Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cytosorbents Corporation?

Cytosorbents Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -5.80.

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Exchange Ticker
NMS (United States) CTSO
FRA (Germany) HQE1.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 5, 2014 1:25
Sept. 8, 2026 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion